GH Research (GHRS) Stock Analysis & Winston Score
GH Research PLC is a clinical-stage biotech company focused on developing treatments for serious mental health conditions. Its lead drug candidate, mebufotenin (also called GH001), is an inhaled form of 5-MeO-DMT, a psychedelic compound being studied as a therapy for treatment-resistant depression. The company targets patients who have not responded to standard antidepressants, a significant unmet medical need. GH Research does not yet generate product revenue, which explains its 0% margins. It is funded through investor capital while it runs clinical trials, a typical model for pre-commercial biotech companies. The company is headquartered in Ireland and operates primarily in Europe and the United States. Its competitive position rests on its proprietary inhaled delivery method, which allows for precise dosing and shorter treatment sessions compared to other psychedelic therapies. The key risk is regulatory approval — if the FDA or EMA does not clear mebufotenin, the company has no fallback commercial product.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (0/30)
- Growth: Weak (2/20)
- Cash Flow: Data not available (0/10)
- Stability: Data not available (0/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)
Key Facts
Price: $28.33
Market Cap: $1.9B
Sector: Healthcare
Industry: Biotechnology
Exchange: NASDAQ

